Menu

Pharma

HomeAll PostsPharma

Organon Partners with BaoPharma to Bring Innovative Long-Acting FSH Treatment to China

Fertility, News, Pharma, Reproductive Health 2 days ago
Share

Organon China has announced a licensing and supply agreement with Shanghai Bao Pharmaceutical (BaoPharma) and its wholly-owned subsidiary, Suzhou Centergene Pharmaceuticals. Through this partnership, Organon acquires the exclusive commercialization rights to Centergene’s investigational asset, SJ02, in Mainland China. SJ02, developed by Centergene, is a long-acting recombinant human follicle-stimulating hormone carboxyl-terminal peptide fusion protein (FSH-CTP). It is designed for controlled ovarian stimulation (COS)…

Bayer Launches New Healthy-Aging Ecosystem

Digital Health, Menopause, News, Pharma September 13, 2024
Share

Bayer has announced the launch of its new healthy-aging ecosystem, Age Factor, a comprehensive platform that combines a scientifically formulated dietary supplement with a wellness companion app and a saliva-based biological age test, powered by Chronomics. This initiative marks Bayer’s first holistic offering from its new Precision Health business unit, aimed at helping consumers take control of their healthy-aging journey. The Age…

Fresenius Kabi Launches New Generic Version of Cetrorelix Acetate for Injection, a Medication Used in Fertility Care

Fertility, News, Pharma August 28, 2024
Share

Fresenius Kabi has launched a new generic version of Cetrorelix Acetate for Injection, a medication used in reproductive health treatments, expanding its portfolio of women’s health products. The new option, which is available immediately, offers a cost-effective alternative for women undergoing fertility treatments. The injection kit includes one single-dose vial (0.25 mg cetrorelix), a pre-filled syringe with sterile water for injection, and…

JAMA Publishes Positive Phase III Results for Bayer’s Elinzanetant in Treating Menopausal Hot Flashes

Menopause, News, Pharma August 23, 2024
Share

Elinzanetant, an investigational non-hormonal treatment for moderate to severe vasomotor symptoms (VMS) associated with menopause, has shown promising results in the pivotal Phase III OASIS 1 and 2 studies. The data, published in The Journal of the American Medical Association (JAMA), highlights the compound’s efficacy in reducing the frequency and severity of hot flashes, commonly referred to as vasomotor symptoms (VMS), while…

Lupin Divests U.S. Women’s Health Specialty Business to Evofem, Including BV Drug SOLOSEC

News, Pharma July 17, 2024
Share

Global pharmaceutical company Lupin has announced the divestiture of its U.S. Commercial Women’s Health Specialty Business to Evofem Biosciences, a biopharmaceutical company dedicated to women’s health. This strategic move includes the transfer of SOLOSEC (secnidazole) 2g oral granules, an FDA-approved antimicrobial agent for treating bacterial vaginosis (BV) and trichomoniasis. The agreement provides Lupin with the opportunity to receive up to USD 84…

FDA Approves Lilly’s Kisunla for Early Symptomatic Alzheimer’s Disease

Brain Health and Cognitive Health, News, Pharma July 12, 2024
Share

Eli Lilly’s Kisunla (donanemab-azbt) has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of early symptomatic Alzheimer’s disease. This includes adults with mild cognitive impairment (MCI) and mild dementia stages of the disease. Alzheimer’s disease affects women disproportionately, with nearly two-thirds of Americans diagnosed being women. The pivotal Phase 3 study, TRAILBLAZER-ALZ 2, showed that Kisunla slowed…

Mika Health, AstraZeneca, and Daiichi Sankyo Team Up to Provide AI-Enabled Support for Women with Breast Cancer

Breast Health, Cancer, Digital Health, News, Partnership, Pharma June 19, 2024
Share

Digital therapeutics company Mika Health has announced a new collaboration with AstraZeneca and Daiichi Sankyo. The initiative, named “UNITE,” aims to enhance the treatment experience for women undergoing breast cancer therapy in Switzerland through the use of Mika Health’s AI-enabled mobile platform. The UNITE initiative was unveiled at the HLTH Europe conference and signifies a significant step towards integrating digital solutions in…

European Medicines Agency Validates Henlius and Organon’s Biosimilar HLX14 for Treating Osteoporosis and Bone Metastasis

Bone Health, Menopause, News, Pharma May 24, 2024
Share

Shanghai Henlius Biotech and women’s health pharma company Organon have announced that the European Medicines Agency (EMA) has validated the marketing authorization applications (MAAs) for HLX14, an investigational biosimilar for Prolia and Xgeva (denosumab). This biosimilar aims to provide an alternative treatment for osteoporosis in postmenopausal women at high risk for fractures and for preventing skeletal-related events in patients with bone metastases.…